Overview
Indications
Hypertension: Captopril tablets, USP, are indicated for the treatment of hypertension. WARNINGS In using captopril tablets, USP, consideration should be given to the risk of neutropenia/agranulocytosis (see). Captopril tablets, USP may be used as initial therapy for patients with normal renal function, in whom the risk is relatively low. In patients with impaired renal function, particularly those with collagen vascular disease, captopril should be reserved for hypertensives who have either deve
Boxed Warning
FDA Black Box Warning
• When pregnancy is detected, discontinue captopril tablets as soon as possible. • Fetal Toxicity Drugs that act directly on the renin-angiotensin system can cause injury and death to the developing fetus. See WARNINGS:
Contraindications
When this intervention should not be used
Captopril is contraindicated in patients who are hypersensitive to this product or any other angiotensin-converting enzyme inhibitor (e.g., a patient who has experienced angioedema during therapy with any other ACE inhibitor). PRECAUTIONS Drug Interactions , Do not co-administer aliskiren with capto
Indications & Related Conditions
Conditions associated via SNOMED clinical relationships
Administration & Protocol
Dosing, route, and treatment protocol
Detailed dosage and administration information is available in the full FDA drug label.
View full prescribing information on DailyMedMonitoring & Follow-Up
Biomarkers relevant to this intervention via related conditions
Clinical Trials
3 trials linked to this intervention
Recent Trials
Safety and Efficacy of Pletal(Cilostazol) for the Treatment of Juvenile Primary and Secondary Raynaud's Phenomenon
Safety and Efficacy of Pletal (Cilostazol) for the Treatment of Juvenile Primary and Secondary Raynaud's Phenomenon
Botulinum Toxin in Raynaud's Phenomenon
Research Evidence
Published studies and systematic reviews
Research data from MEDLINE/PubMed
Benefits & Expected Outcomes
Benefits, expected outcomes, efficacy data, and NNT (Number Needed to Treat) are pending physician authorship and evidence review.
Risks & Side Effects
Adverse reaction and safety data for this drug is sourced from the FDA-approved label.
View adverse reactions & drug interactions on DailyMedRelated Symptoms
Symptoms associated with conditions this intervention addresses
No related symptoms have been mapped yet. Symptom linkages are derived through associated conditions.
Alternatives & Comparisons
Alternative treatments, comparison data, and clinical decision support are pending physician authorship.
This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.
Do not start, stop, or change any treatment without consulting your healthcare provider.
Specialists
Providers who commonly manage this intervention
Health Goals
Goals connected through associated conditions
Quick Facts
- Type
- Substance / Medication
- Fully Specified Name
- Captopril (substance)
- SNOMED CT
- 387160004
- UMLS CUI
- C0006938
- RxNorm CUI
- 1998
- Labeler
- Major Pharmaceuticals
Clinical Data
This intervention maps to 17 entities in the Healos knowledge graph.
Data is sourced from SNOMED CT, UMLS, and the Healos clinical knowledge graph. Content sections marked as pending require physician authorship. Consult a healthcare provider before starting any treatment.